Assessing the patient impact and burden of current care pathways in Barrett’s Oesophagus

Wrightington, Wigan And Leigh NHS Foundation Trust0 个研究点目标入组 750 人开始时间: 2017年11月1日最近更新: 2023年1月9日

试验速览

2017 Results article in https://pubmed.ncbi.nlm.nih.gov/28867477/ results (added 09/11/2020) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/30430714/ results (added 09/11/2020) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/31205652/ results (added 09/11/2020) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32337055/ results (added 09/11/2020)

•1. Must have capacity to give informed consent
•2. >18 years old. No upper age limit.
•3. Male or Female
•4. Meet the diagnostic criteria for each group
•4.1. Non-Dysplastic Barrett’s Oesophagus. All patients enrolled in surveillance who have been given a diagnosis of BO irrespective of current histology (lack of intestinal metaplasia on latest biopsies is not a criterion for exclusion providing future surveillance is indicated/recommended)
•4.2. Barrett’s oesophagus with dysplasia or early oesophageal adenocarcinoma. Any patient with BO diagnosed with low grade dysplasia, high grade dysplasia or early OAC eligible for ET.
•4.3. Colonic Polyps. Participants currently undergoing endoscopic surveillance for colonic polyps
•4.4. Gastro-oesophageal reflux disease. Participants without BO who have been diagnosed with any of the following; gastroesophageal reflux + oesophagitis”, gastroesophageal reflux – oesophagitis”, gastroesophageal reflux disease”, GORD”, acid reflux” or heartburn”, dyspepsia”.
•4.5. Normal Healthy Individuals. Population control participants who do not exhibit significant co-morbidities

发起方